I'm considering offering GLP peptides exclusively to members of this group. If I move forward with this, all products would be: ✅ Third-party laboratory tested ✅ Accompanied by Certificates of Analysis (CoAs) ✅ Sourced with transparency and quality as the priority Before I spend the time and resources researching this further, I'd like to know what the community would actually want. Which GLP peptide would you be most interested in purchasing? 🌟Tirzepatide (Tirz) 🌟Retatrutide (Reta) 🌟Semaglutide (Sema) In the comments, tell me: 1. Which peptide you would be most interested in. 2. What vial size (mg) you would prefer (e.g., 10mg, 15mg, 30mg, etc.). 3. What is most important to you when choosing a supplier (price, testing, purity, shipping speed, customer support, etc.). Your feedback will help determine whether this is something worth pursuing for the group.

Has anyone made the leap from tirz to reta? I've been doing tirz for over a year. I'm making no progress (20 pounds in 1+ year feels like nothing). I have not maxxed out on dose because I feel I definitely need to consume more calories than that would allow. I force myself to eat on 7.5 of tirz. I'm looking for what happened when you made the switch. The good and the bad. Thank you

What is Cagrilintide? Cagrilintide (also known as AM833/NNC0174-0833) is a long-acting synthetic amylin analogue and dual amylin/calcitonin receptor agonist (DACRA). It mimics the hormone amylin, which is co-secreted with insulin and helps regulate appetite and slow gastric emptying — mechanisms that support weight control and metabolic health. It is being developed for weight management and type 2 diabetes, and has been studied alone and in combination with GLP-1 receptor agonists (e.g., semaglutide) under names like CagriSema. Benefits: 1. Appetite Suppression and Satiety Cagrilintide activates amylin pathways in the brain helping you feel fuller, reduce hunger signals, and eat less overall. 2. Weight Loss In trials: ● As monotherapy, it produces significant weight reduction. ● In combination with semaglutide (CagriSema), mean weight loss up to ~22.7% has been reported, a very high efficacy among obesity meds. 3. Metabolic Improvements Studies show better glycemic control (lower HbA1c) and improvements in metabolic markers like triglycerides and insulin sensitivity. 4. Convenient Dosing Once-weekly subcutaneous injections make it easy to integrate into regimens similar to GLP-1 therapies. Dosing: Because cagrilintide is not FDA-approved yet, dosing schedules vary across clinical studies. The common theme is gradual weekly titration to help reduce side effects. If using a GLP, dose Cagrilintide 2-3 days after your GLP injection. A typical dose escalation in trials looked like: ● Weeks 1–4: ~0.25–0.3 mg/week ● Weeks 5–8: ~0.5–0.6 mg/week ● Weeks 9–12: ~1.0–1.2 mg/week ● Weeks 13–16: ~1.7–2.4 mg/week ● Maintenance: ~2.4 mg/week (some trials explored up to 4.5 mg) Maximum doses in research did not exceed ~4.5 mg/week. Combination with Semaglutide (CagriSema) Clinical trial protocols often matched cagrilintide titration with semaglutide escalation: ● Cagrilintide → 0.6 → 1.2 → 1.8 → 2.4 mg weekly ● Semaglutide → 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly